Autolus Therapeutics specialises in T cell programming technology for the treatment of cancer.

It is engineering precisely targeted, controlled and highly active T cell therapies designed to better recognise cancer cells, break down their defence mechanisms and eliminate them.

Founded on advanced cell programming technology pioneered by Dr Martin Pule, the business was spun out from University College London in 2014.

Back to BusinessCloud’s 101 HealthTech Innovators